ClinicalTrials.gg
RecruitingNCT07937267Updated Nov 16, 2026

Cytological Assessment of Donor-Site Healing After Free Gingival Grafting

An interventional study of Free gingival graft and Chitosan sponge in Free Gingival Graft Donor Site, sponsored by Biruni University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Biruni University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2026, registered Nov 2026).
  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

An adequate width of keratinized gingiva is important for maintaining periodontal and peri-implant tissue health. Free gingival grafting (FGG) is a commonly performed surgical procedure for increasing insufficient keratinized gingival width. This study aims to evaluate the effect of applying a chitosan sponge to the palatal donor site on wound healing after FGG using exfoliative cytology and to compare the findings with those obtained from a control group in which no chitosan sponge is applied.

At least 40 patients scheduled to undergo FGG because of insufficient keratinized gingival width will be included. The patients will be allocated to two groups: a test group and a control group. In the test group, a chitosan sponge will be applied to the palatal donor site, whereas no wound dressing will be applied to the palatal donor site in the control group. The primary outcome will be the keratinization index determined from cytological samples collected from the palatal donor site at one month after surgery. The keratinization index values at one month will be compared between the test and control groups.

All participants will receive detailed information about the study and the procedures, and written informed consent will be obtained. Clinical measurements will be recorded before surgery, after which the FGG procedure will be performed. Depending on group allocation, the palatal donor site will either be treated with a chitosan sponge or left without a wound dressing. Sutures will be removed on postoperative day 10.

For exfoliative cytological assessment, baseline samples will be collected from both the planned palatal donor site and the contralateral symmetrical healthy palatal site, which will not undergo surgery, in all patients. Samples collected from the symmetrical palatal site will serve as a reference for the baseline characteristics of healthy palatal mucosa. Follow-up samples will be collected exclusively from the palatal donor site on postoperative day 3,10 and at 1, 3, and 6 months. The keratinization index and other cellular features associated with wound healing will be assessed in the cytological samples. Findings obtained during the follow-up periods will be compared between the test group treated with a chitosan sponge and the control group in which no wound dressing is applied. In addition, the presence or absence of sensory loss at the palatal donor site will be evaluated using a periodontal probe.

02

Conditions studied

  • Free Gingival Graft Donor Site
03

In context

Lead sponsor

Biruni University is the lead sponsor of 181 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteering to participate in the study,
  • Being at least 18 years of age,
  • The need for SDG in patients with \< 2 mm of keratinized gingiva on the vestibular side of the implant/tooth,
  • No prior surgical procedures or grafts in the palatal region,Volunteering to participate in the study,

Exclusion criteria

Exclusion Criteria:

  • The presence of a systemic disease that would contraindicate surgical treatment,
  • Uncontrolled diabetes ( > 7),
  • Pregnancy or breastfeeding,
  • and/or inflammatory diseases of the oral cavity,
  • Active periodontal disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Test

    Procedure: Free gingival graft · Other: Chitosan sponge

  • Active comparator
    Control

    Procedure: Free gingival graft

Interventions

  • ProcedureFree gingival graft

    Free gingival graft surgery

  • OtherChitosan sponge

    Suturing of chitosan sponge to the palatal donor site

06

What researchers measure

Primary outcomes

  1. Palatal donor site tissue thickness:

    The thickness of the donor site will be measured using an endodontic reamer.

    Time frame: Pre-operative

  2. Palatal donor site tissue thickness:

    The thickness of the donor site will be measured using an endodontic reamer.

    Time frame: immediate Post-operative

  3. Palatal donor site tissue thickness:

    The thickness of the donor site will be measured using an endodontic reamer.

    Time frame: day 10

  4. Palatal donor site tissue thickness:

    The thickness of the donor site will be measured using an endodontic reamer.

    Time frame: day 30

  5. Palatal donor site tissue thickness:

    The thickness of the donor site will be measured using an endodontic reamer.

    Time frame: day 90

  6. Palatal donor site tissue thickness:

    The thickness of the donor site will be measured using an endodontic reamer.

    Time frame: day 180

  7. Keratinization Index

    Cells without nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 3

  8. Keratinization Index

    Cells without nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 10

  9. Keratinization Index

    Cells without nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 30

  10. Keratinization Index

    Cells without nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 90

  11. Keratinization Index

    Cells without nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 180

  12. Superficial cell index

    Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 3

  13. Superficial cell index

    Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 10

  14. Superficial cell index

    Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 30

  15. Superficial cell index

    Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 90

  16. Superficial cell index

    Total number of cells with and without pyknotic nuclei / Total number of cells examined (n=200) × 100

    Time frame: day 180

Secondary outcomes

  1. Loss of sensation

    To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

    Time frame: Day 10

  2. Loss of sensation

    To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

    Time frame: Day 30

  3. Loss of sensation

    To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

    Time frame: Day 90

  4. Loss of sensation

    To test it objectively, two different movements will be performed with the tip of the probe: immersion and scraping.

    Time frame: Day 180

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937267
Lead sponsor
Biruni University
Responsible party
Ayse Ege SELMAN (Assistant Prof, Biruni University) — Principal investigator
First posted
Nov 16, 2026
Start date
Jul 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion